

Press Release

For Immediate Release

China Pharmaceutical Innovation and Research Development Association Visits Hong Kong Science Park

Promoting Local and National Biomedical Development

Key Takeaways

- Prof Dong Sun, Secretary for Innovation, Technology and Industry affirms mission to power biotech industry
- PhIRDA and HKSTP to forge closer strategic cooperation between industry and the academia
- Hong Kong to attract global talent and corporations as the GBA's most globalised city

(Hong Kong, 3 March 2023) - A delegation from the China Pharmaceutical Innovation and Research Development Association (PhIRDA) visited Hong Kong Science Park to understand the latest achievements in the development of biomedical industry in Hong Kong, and explored how to further accelerate the biomedicine development process in Hong Kong and China. Mr Albert Wong, Chief Executive Officer of Hong Kong Science and Technology Parks Corporation (HKSTP), led the management team to host the delegation, while Professor Dong Sun, Secretary for Innovation, Technology and Industry, also participated in the event to share views on the Hong Kong Innovation and Technology Development Blueprint and the latest biomedical policies with 30 representatives from 23 pharmaceutical companies (of which 12 are listed).

Professor Dong Sun, Secretary for Innovation, Technology and Industry, said, "Hong Kong has the unique advantages of 'enjoying strong support from the Motherland and being closely connected to the world', which we believe can help the country's biomedical technology to go global. Hong Kong will strive to create favourable conditions for the development of related industries, and I hope everyone can seize this opportunity to jointly promote local and national biomedical technology into a new era."

Mr Albert Wong, Chief Executive Officer of HKSTP, said, "HKSTP welcomes the representatives of PhIRDA to the Hong Kong Science Park. We provide comprehensive support to our partner companies and startups, actively promote collaboration among stakeholders from government, industry, academic, and research sectors, and set up the Institute for Translational Research (ITR) in 2021 to facilitate collaboration between international, local and Mainland biopharmaceutical enterprises to expedite the translation journey of biomedical technologies."

Annual Chairman of PhIRDA & Director General of SIMM, Professor Li Jia, said, "As a leading association in the field of biomedicine in China, PhIRDA hopes to facilitate communication between the industry and the government through this visit, and to establish closer strategic cooperation between industry and the academia to jointly promote the development of the national innovation & technology (I&T) industry."

Professor Song Ruilin, Executive President of PhIRDA, said, "Hong Kong is the most globalised city in the Greater Bay Area and plays an important role in recruiting overseas talents. PhIRDA hopes to bring more outstanding pharmaceutical companies to Hong Kong, and accelerate the engagement of Chinese enterprises with international standards by leveraging the advantages of Hong Kong's "one country, two systems". Professor Song Ruilin further suggested that Hong Kong should take the lead in internationalisation of regulation."

The delegation visited Science Park's core facilities such as the [Biomedical Technology Support Centre \(BSC\)](#), the [Incu-Bio](#) co-working lab, and the [GLP Drug Safety Testing Centre \(DSC\)](#). Dr Grace Lau, Head of Institute for Translational Research of HKSTP, briefed the delegation on Hong Kong's biomedical technology's translation and ecosystem, and acknowledged the views and suggestions on the development of Hong Kong's biomedical industry in terms of regulatory supervision, clinical translation and industrial implementation. Dr Grace Lau said that ITR provides support to partner companies at different stages of development through continuously improving the core facilities and services to accelerate the translational journey of biomedical technology.



Photo 1: Professor Dong Sun, Secretary for Innovation, Technology and Industry (first from left), said that Hong Kong will strive to create favourable conditions for the development of the biomedical technology industry.



Photo 2: Mr Albert Wong, Chief Executive Officer of HKSTP, said HKSTP actively promotes collaboration among stakeholders from government, industry, academic, and research sectors, and supports partner companies and startups to accelerate the biomedical technology translational journey.



Photo 3: Professor Li Jia (right), Annual Chairman of PhIRDA & Director General of SIMM, said that through this visit, PhIRDA hopes to establish closer strategic collaborations for the industry, government and academia to jointly promote the development of the national I&T industry.



Photo 4: A delegation from PhIRDA visited Hong Kong Science Park to meet and exchange views with Professor Sun Dong, Secretary for Innovation, Technology and Industry, and Mr Albert Wong, Chief Executive Officer of HKSTP together with its management team.

###

About Hong Kong Science and Technology Parks Corporation

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to three unicorns and Hong Kong's leading R&D hub with over 12,000 research professionals and over 1,200 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimaged for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's

international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at www.hkstp.org.

About PhIRDA

Pharmaceutical Innovation and Research Development Association (PhIRDA), founded in 1988, is registered as a non-profit 4A social organization by the Ministry of Civil Affairs of China at national level. PhIRDA has been exerting great effort on "academia-industry-investment collaboration", which centers on the principle of "innovation, industrialization, internationalization", and persists in innovation to achieve unmet clinical requirements. As a platform facilitating the industrialization of pharmaceutical innovation, PhIRDA currently has 182 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical innovation. Moreover, PhIRDA has established the following Specialty Committees: Drug R&D, Clinical Trial Research, Medicinal Policy, Pharmaceutical Innovation Investment and Innovation R&D Services, Clinical Research on Cardiovascular Drugs, International Regulatory Science, Clinical Research on Oncology Drugs, Clinical Research on Cranial Nerve Drugs, Ethics and Business Compliance, Clinical Research on Diabetes and Metabolic Diseases, forming a fully

functional organization structure focusing on innovation, aiming to promote the development of innovation, covering the whole industrial chain, including drug R&D, manufacturing, using, investment and capital market. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.

Media Contact

**Hong Kong Science and Technology Parks
Corporation**

Claire Ma

Phone: +852 2629 7032

Email: claire.ma@hkstp.org

Edelman Public Relations

Lisa Tse

Tel: +852 3756 8632 / 6347 2009

Email: Lisa.Tse@edelman.com /

Edelmanhkstppr@edelman.com